Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Oscar Health Inc (NYSE: OSCR) closed at $16.63 in the last session, down -0.12% from day before closing price of $16.65. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 30.43 million shares were traded. OSCR stock price reached its highest trading level at $17.705 during the session, while it also had its lowest trading level at $16.305.
Ratios:
We take a closer look at OSCR’s different ratios to gain a better understanding of the stock. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
On July 15, 2025, UBS Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $11.
Piper Sandler Downgraded its Overweight to Neutral on July 14, 2025, while the target price for the stock was maintained at $14.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 20 ’25 when RANMALI BOPITIYA bought 30,000 shares for $18.77 per share.
ALESSANDREA QUANE bought 148,280 shares of OSCR for $2,598,488 on May 16 ’25. On May 12 ’25, another insider, Robinson Elbert O. Jr., who serves as the Director of the company, sold 25,000 shares for $16.43 each. As a result, the insider received 410,750 and left with 64,512 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OSCR now has a Market Capitalization of 4299819520 and an Enterprise Value of 1117699072. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.39 while its Price-to-Book (P/B) ratio in mrq is 3.71. Its current Enterprise Value per Revenue stands at 0.104 whereas that against EBITDA is -11.286.
Stock Price History:
The Beta on a monthly basis for OSCR is 1.87, which has changed by -0.018299878 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, OSCR has reached a high of $23.79, while it has fallen to a 52-week low of $11.20. The 50-Day Moving Average of the stock is 4.57%, while the 200-Day Moving Average is calculated to be 10.72%.
Shares Statistics:
According to the various share statistics, OSCR traded on average about 25.52M shares per day over the past 3-months and 21619420 shares per day over the past 10 days. A total of 222.91M shares are outstanding, with a floating share count of 186.10M. Insiders hold about 26.93% of the company’s shares, while institutions hold 56.80% stake in the company. Shares short for OSCR as of 1753920000 were 60082746 with a Short Ratio of 2.35, compared to 1751241600 on 28587987. Therefore, it implies a Short% of Shares Outstanding of 60082746 and a Short% of Float of 29.950001999999998.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is -$0.98, with high estimates of -$0.85 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$1.01 and -$1.91 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$0.32, with 7.0 analysts recommending between $0.16 and -$1.06.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $3.09B. It ranges from a high estimate of $3.13B to a low estimate of $3.05B. As of the current estimate, Oscar Health Inc’s year-ago sales were $2.42BFor the next quarter, 7 analysts are estimating revenue of $3.06B. There is a high estimate of $3.09B for the next quarter, whereas the lowest estimate is $3.03B.
A total of 7 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $12.11B, while the lowest revenue estimate was $11.99B, resulting in an average revenue estimate of $12.06B. In the same quarter a year ago, actual revenue was $9.18BBased on 7 analysts’ estimates, the company’s revenue will be $11.31B in the next fiscal year. The high estimate is $12.13B and the low estimate is $10.9B.
